FindTrial
Sign In

Controlled study for Efficacy and Safety of Rivastigmine Transdermal Patch in Patients With Mild to Moderate Alzheimer's Disease

Controlled study for Efficacy and Safety of Rivastigmine Transdermal Patch in Patients With Mild to Moderate Alzheimer's Disease

Status
Unknown
Phases
Phase 3
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080220356
Enrollment
Unknown
Registered
2007-03-12
Start date
2007-03-12
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer's Disease

Interventions

investigational material(s) Generic name etc : rivastigmine INN of investigational material : Therapeutic category code : 119 Other agents affecting central nervous system Dosage and Administration f

Sponsors

Novartis Pharma K.K., ONO Pharmaceutical Co., Ltd.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Inclusion criteria 1.A diagnosis of dementia of the Alzheimer's type according to the DSM-IV criteria 2.A clinical diagnosis of probable AD according to NINCDS/ADRDA criteria 3.An MMSE score of >= 10 and = 20 Exclusion criteria 1.A current DSM-IV diagnosis of major depression 2.Taken rivastigmine in the past 3.A score of > 5 on the Modified Hachinski Ischemic Scale (MHIS) Other protocol-defined inclusion/exclusion criteria may apply

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Safety /Efficacy—

Contacts

Public Contact; ;

Novartis Pharma KK;Ono pharmaceutical Co., Ltd.

;;

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026